Rett Syndrome Treatment Market Faces Regulatory Challenges While Acadia Strengthens Pipeline

Acadia Pharmaceuticals is navigating a complex regulatory landscape as its Rett syndrome drug trofinetide encounters headwinds in the European market, yet the company continues to capitalize on robust domestic sales growth. The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has signaled an unfavorable stance toward Acadia’s marketing application for trofinetide in treating Rett syndrome, with a formal negative opinion anticipated this month. The company plans to pursue a re-examination request following the official CHMP decision. This regulatory setback could delay European market entry for what remains the only FDA-approved treatment option for this rare neurodevelopmental disorder affecting approximately 1 in 10,000 to 15,000 female births globally.

Rett syndrome presents a significant unmet medical need, with symptoms typically emerging between six and 18 months of age, characterized by progressive motor and cognitive decline. The FDA approved trofinetide for Rett syndrome treatment in 2023, recognizing its therapeutic value for both adult and pediatric patients aged two years and older. Despite the European regulatory challenge, Acadia’s commitment to this patient population continues through expanding treatment options.

Daybue’s Strong Sales Momentum in Rett Syndrome Market

Acadia’s branded formulation of trofinetide, marketed as Daybue in the United States, has demonstrated impressive commercial traction since its 2023 launch. During the first nine months of 2025, Daybue generated $281.8 million in sales, reflecting 12% year-over-year growth driven primarily by increased unit volume and expanding patient reach. The company’s success stems from its direct-to-patient approach, with healthcare providers dispensing the medication to more unique patients as clinical experience with Rett syndrome treatment broadens.

The recent FDA approval of Daybue Stix represents a significant expansion of Acadia’s therapeutic arsenal in this indication. This new dye- and preservative-free powder formulation addresses specific patient needs and administration preferences, diversifying the company’s portfolio within Rett syndrome treatment. Acadia plans a limited market introduction during Q1 2026, with broader national availability anticipated in the subsequent quarter. The dual-formulation strategy—maintaining the existing oral solution alongside the new powder option—strengthens Acadia’s competitive positioning and accessibility in the Rett syndrome market.

Regulatory Setback in EU Amid Growing Rett Syndrome Treatment Options

The negative CHMP recommendation marks a significant obstacle to Acadia’s international expansion strategy for Rett syndrome treatment. However, the company’s re-examination pathway offers a potential avenue for addressing regulatory concerns. This delay may temporarily limit geographic market penetration but does not diminish the clinical value proposition of trofinetide in treating Rett syndrome in other regions.

Industry experts project that the Rett syndrome treatment landscape will continue evolving, with FDA-approved therapies gaining clinical acceptance and generating compelling real-world evidence. Acadia’s position as the current monopoly holder in this therapeutic area remains defensible given the unmet medical need and limited competing options for this patient population.

Long-Term Growth Potential Supported by Patent Protection and Expanding Pipeline

Beyond Rett syndrome, Acadia’s broader pharmaceutical portfolio demonstrates considerable growth potential. Nuplazid, the company’s flagship treatment for hallucinations and delusions associated with Parkinson’s disease psychosis, recorded $505.7 million in sales during the first nine months of 2025, representing 13% year-over-year expansion. The drug maintains patent exclusivity in the United States through 2038, providing over a decade of protection against generic competition and continued revenue generation.

Acadia management projects combined net sales of approximately $1.7 billion by 2028 across its marketed products, with Nuplazid contributing roughly $1 billion and Daybue-inclusive products contributing approximately $700 million. This diversified revenue base, anchored by two commercially successful FDA-approved therapies including robust Rett syndrome treatment sales, positions the company for sustained profitability despite current European regulatory uncertainties.

The company’s strategic focus on rare neurological and psychiatric indications, coupled with its success in establishing market leadership within the Rett syndrome treatment segment, underscores Acadia’s capacity to generate long-term shareholder value even as international regulatory challenges emerge. The expanding Rett syndrome therapeutic arsenal—now supported by multiple formulation options—reinforces Acadia’s commitment to serving this patient population with limited alternative treatment choices.